Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
CADILA HEALTHCARE | STERLING BIOTECH | CADILA HEALTHCARE/ STERLING BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 28.5 | -0.4 | - | View Chart |
P/BV | x | 5.0 | 0.0 | 35,020.5% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
STERLING BIOTECH Dec-13 |
CADILA HEALTHCARE/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 11 | 3,355.2% | |
Low | Rs | 207 | 3 | 6,073.5% | |
Sales per share (Unadj.) | Rs | 139.2 | 26.8 | 519.4% | |
Earnings per share (Unadj.) | Rs | 11.8 | -15.0 | -78.7% | |
Cash flow per share (Unadj.) | Rs | 18.6 | -5.5 | -339.9% | |
Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.4 | 54.9 | 184.7% | |
Shares outstanding (eoy) | m | 1,023.74 | 267.87 | 382.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 0.3 | 774.0% | |
Avg P/E ratio | x | 23.7 | -0.5 | -5,110.9% | |
P/CF ratio (eoy) | x | 15.0 | -1.3 | -1,182.7% | |
Price / Book Value ratio | x | 2.8 | 0.1 | 2,176.9% | |
Dividend payout | % | 29.8 | 0 | - | |
Avg Mkt Cap | Rs m | 286,033 | 1,862 | 15,364.1% | |
No. of employees | `000 | 13.4 | 1.4 | 990.0% | |
Total wages/salary | Rs m | 24,145 | 547 | 4,415.7% | |
Avg. sales/employee | Rs Th | 10,632.7 | 5,303.3 | 200.5% | |
Avg. wages/employee | Rs Th | 1,801.2 | 403.8 | 446.0% | |
Avg. net profit/employee | Rs Th | 898.5 | -2,959.0 | -30.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 7,181 | 1,984.9% | |
Other income | Rs m | 1,139 | 43 | 2,673.7% | |
Total revenues | Rs m | 143,670 | 7,223 | 1,989.0% | |
Gross profit | Rs m | 24,198 | 947 | 2,555.5% | |
Depreciation | Rs m | 6,965 | 2,543 | 273.9% | |
Interest | Rs m | 3,418 | 4,377 | 78.1% | |
Profit before tax | Rs m | 14,954 | -5,931 | -252.1% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | -1,924 | -166.2% | |
Profit after tax | Rs m | 12,044 | -4,007 | -300.6% | |
Gross profit margin | % | 17.0 | 13.2 | 128.7% | |
Effective tax rate | % | 21.4 | 32.4 | 65.9% | |
Net profit margin | % | 8.5 | -55.8 | -15.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 14,335 | 608.0% | |
Current liabilities | Rs m | 82,694 | 49,809 | 166.0% | |
Net working cap to sales | % | 3.1 | -494.0 | -0.6% | |
Current ratio | x | 1.1 | 0.3 | 366.2% | |
Inventory Days | Days | 71 | 403 | 17.7% | |
Debtors Days | Days | 94 | 171 | 55.0% | |
Net fixed assets | Rs m | 133,236 | 55,432 | 240.4% | |
Share capital | Rs m | 1,024 | 268 | 382.2% | |
"Free" reserves | Rs m | 102,733 | 13,935 | 737.2% | |
Net worth | Rs m | 103,757 | 14,701 | 705.8% | |
Long term debt | Rs m | 32,146 | 9,478 | 339.2% | |
Total assets | Rs m | 236,866 | 73,988 | 320.1% | |
Interest coverage | x | 5.4 | -0.4 | -1,514.3% | |
Debt to equity ratio | x | 0.3 | 0.6 | 48.1% | |
Sales to assets ratio | x | 0.6 | 0.1 | 620.0% | |
Return on assets | % | 6.5 | 0.5 | 1,303.2% | |
Return on equity | % | 11.6 | -27.3 | -42.6% | |
Return on capital | % | 13.7 | -6.4 | -213.7% | |
Exports to sales | % | 0 | 25.9 | 0.0% | |
Imports to sales | % | 0 | 0.2 | 0.0% | |
Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
Imports (cif) | Rs m | NA | 12 | 0.0% | |
Fx inflow | Rs m | 52,752 | 1,860 | 2,836.4% | |
Fx outflow | Rs m | 14,504 | 25 | 58,272.4% | |
Net fx | Rs m | 38,248 | 1,835 | 2,084.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 1,719 | 1,457.7% | |
From Investments | Rs m | -10,123 | -3,148 | 321.5% | |
From Financial Activity | Rs m | -10,942 | 1,426 | -767.3% | |
Net Cashflow | Rs m | 3,989 | -3 | -117,323.5% |
Indian Promoters | % | 74.8 | 33.9 | 220.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.3 | 0.0 | - | |
FIIs | % | 5.9 | 9.9 | 59.6% | |
ADR/GDR | % | 0.0 | 16.9 | - | |
Free float | % | 11.0 | 39.3 | 28.0% | |
Shareholders | 44,069 | 21,482 | 205.1% | ||
Pledged promoter(s) holding | % | 0.0 | 55.9 | - |
Compare CADILA HEALTHCARE With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE J.B.CHEMICALS ASTRAZENECA PHARMA BIOCON
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.
For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More